Vermillion (VRML) Stock Price, News & Analysis

Company Overview

Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women. It also offers in-vitro diagnostic (IVD) trial services to third-party customers; and laboratory services to meet the needs of IVD manufacturers to commercialize high-complexity assays. The company serves clinical reference laboratories, hospital laboratories, and physician offices. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.

Key Stats

• Today's Range: $0.16 to $0.20
• 50-Day Range: $2.54 to $4.24
• 52-Week Range: $0.35 to $5.78
• Volume: 284,437 shs
• Average Volume: 440,144 shs
• Market Capitalization: $19.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VRML Stock Analysis - Frequently Asked Questions

How were Vermillion's earnings last quarter?

Vermillion, Inc. (NASDAQ:VRML) released its earnings results on Thursday, August, 8th. The company reported ($0.06) earnings per share (EPS) for the quarter. The company earned $1.14 million during the quarter. Vermillion had a negative net margin of 307.31% and a negative trailing twelve-month return on equity of 155.25%.

What other stocks do shareholders of Vermillion own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vermillion investors own include CombiMatrix (CBMX), Accelerate Diagnostics (AXDX), Himax Technologies (HIMX), Charter Communications (CHTR), Idera Pharmaceuticals (IDRA), Magnachip Semiconductor (MX) and Cardiff Oncology (TROV).

Company Calendar

• Last Earnings: 8/08/2019
• Today: 7/10/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic Substances
• Sub-Industry: N/A
• Current Symbol: NASDAQ:VRML
• CIK: 926617
• Web: www.vermillion.com
• Phone: 512-519-0400
• Fax: N/A
• Employees: 43
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.24 million
• Net Margins: -307.31%
• Pretax Margin: N/A
• Return on Equity: -155.25%
• Return on Assets: -103.47%

Debt

• Debt-to-Equity Ratio: 0.20
• Current Ratio: 2.51
• Quick Ratio: 2.49

Sales & Book Value

• Annual Sales: $4.54 million
• Price / Sales: 4.29
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.09 per share
• Price / Book: 2.22

Miscellaneous

• Outstanding Shares: 97,378,000
• Free Float: N/A
• Market Cap: $19.48 million
• Optionable: Not Optionable
• Beta: 3.47